Helse Bergen would lik to have a dialogue with interested parties in the market that would like to participate in the development of a system for drying blood plasma used to treat patients with life-threatening bleeding.
Helse Bergen has up to NOK 13.5 million that will be used for the development of an innovative system for the production of dried blood plasma for use in the treatment of patients with life-threatening bleeding.
The resources have been granted from Innovasjon Norge and Helse Bergen will make a procurement in accordance with the procedure for an innovation partnership.
We will present our need for more efficient and predictable access to this vital product, which is absolutely vital in many different acute situations. Furthermore, we would like input from companies on the proposal for solutions and interest in a cooperation on such a solution - either with individual suppliers or through a cooperation between several suppliers. The aim of the market dialogue is to clarify whether potential suppliers have understood our needs and to see the feasibility for solutions and any challenges in the project. Input from the market at the dialogue conference will form the basis for the preparation of the tender documentation and final needs description, the aim and functional requirements.Input from the market at the dialogue conference will form the basis for the documentation and the description of the final challenges, the goals and functional requirements.
Target group: Potential suppliers of innovative solutions that can contribute to solving the challenge by producing dried blood plasma. This includes developers of technology for drying blood plasma, manufacturers or packaging, developers of IT systems, and design competence.
See the attached invitation to a market dialogue for further details on the need and how the dialogue conference will be held.
